HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis.
Adolescent
Adult
Alleles
Antigens, CD
/ genetics
Child
Child, Preschool
Female
Gene Expression Regulation
Genetic Predisposition to Disease
HLA-DRB1 Chains
/ genetics
Homozygote
Humans
Infant
Leishmaniasis, Visceral
/ genetics
Lymphocytes
Male
Myeloid Cells
Polymorphism, Single Nucleotide
Risk Factors
HLA-DR
MHC Class II expression
lymphoid lineage
myeloid lineage
visceral leishmaniasis
Journal
Immunology
ISSN: 1365-2567
Titre abrégé: Immunology
Pays: England
ID NLM: 0374672
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
23
08
2018
revised:
22
10
2018
accepted:
29
10
2018
pubmed:
8
11
2018
medline:
6
8
2019
entrez:
8
11
2018
Statut:
ppublish
Résumé
Genetic variation at HLA-DRB1 is a risk factor for visceral leishmaniasis (VL) caused by Leishmania donovani. The single nucleotide polymorphism rs9271252 upstream of the DRB1 gene provides a perfect tag for protective versus risk HLA-DRB1 four-digit alleles. In addition to the traditional role of the membrane-distal region of HLA class II molecules in antigen presentation and CD4 T-cell activation, the membrane-proximal region mediates 'non-traditional' multi-functional activation, differentiation, or death signals, including in DR-expressing T cells. To understand how HLA-DR contributes to disease pathogenesis, we examined expression at the protein level in circulating myeloid (CD14
Identifiants
pubmed: 30403401
doi: 10.1111/imm.13018
pmc: PMC6328996
doi:
Substances chimiques
Antigens, CD
0
HLA-DRB1 Chains
0
Banques de données
GENBANK
['rs9271252']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Pagination
174-186Subventions
Organisme : NIH HHS
ID : 1P50AI074321-01
Pays : United States
Informations de copyright
© 2018 John Wiley & Sons Ltd.
Références
J Exp Med. 1979 Aug 1;150(2):246-55
pubmed: 88499
Front Immunol. 2018 Mar 27;9:616
pubmed: 29636753
Nat Genet. 2013 Feb;45(2):208-13
pubmed: 23291585
J Exp Med. 2007 Apr 16;204(4):805-17
pubmed: 17389235
Nat Rev Immunol. 2014 Nov;14(11):719-30
pubmed: 25324123
J Immunol. 2011 Apr 1;186(7):3977-85
pubmed: 21357266
J Immunol. 2004 Nov 15;173(10):6200-10
pubmed: 15528357
Am J Trop Med Hyg. 2017 Sep;97(3):767-770
pubmed: 28820688
J Immunol. 2006 Apr 15;176(8):4622-31
pubmed: 16585553
Genet Epidemiol. 2001 Apr;20(3):383-96
pubmed: 11255246
J Immunol. 2018 Apr 15;200(8):2727-2737
pubmed: 29507109
Immunol Today. 1991 Mar;12(3):A58-61
pubmed: 1829891
Indian J Exp Biol. 1991 Dec;29(12):1101-3
pubmed: 1816092
Trends Immunol. 2007 Sep;28(9):378-84
pubmed: 17689290
F1000Res. 2016 Mar 17;5:
pubmed: 27006762
Int J Parasitol. 2003 Feb;33(2):153-62
pubmed: 12633653
Parasite Immunol. 2010 Jul;32(7):479-83
pubmed: 20591118
J Clin Immunol. 2015 Jan;35(1):56-67
pubmed: 25479930
J Infect Dis. 2011 Oct 1;204(7):1134-7
pubmed: 21881130
Immunity. 1998 Feb;8(2):157-66
pubmed: 9491997
Cytokine. 1995 Oct;7(7):740-5
pubmed: 8580385
Eur J Immunol. 1994 Jan;24(1):71-5
pubmed: 7517364
J Infect Dis. 1998 Mar;177(3):815-8
pubmed: 9498473
Am J Trop Med Hyg. 1995 Apr;52(4):364-5
pubmed: 7741179
Infect Immun. 2010 Sep;78(9):3736-43
pubmed: 20566692
Hum Immunol. 2004 Apr;65(4):282-90
pubmed: 15120183
Am J Trop Med Hyg. 1997 May;56(5):522-5
pubmed: 9180602
Eur J Immunol. 2012 Oct;42(10):2608-20
pubmed: 22777759
J Immunol Methods. 2004 Oct;293(1-2):127-42
pubmed: 15541283
PLoS One. 2015 Nov 18;10(11):e0143063
pubmed: 26581100
Nature. 2002 Dec 5;420(6915):502-7
pubmed: 12466842
J Infect Dis. 1992 Mar;165(3):535-40
pubmed: 1347057
J Clin Invest. 1993 Apr;91(4):1644-8
pubmed: 8097208
Cell Immunol. 1988 Nov;117(1):22-34
pubmed: 3263216